IJCM  Vol.5 No.12 , June 2014
The Use of Antiepileptic Drugs in Acute Neuropsychiatric Conditions: Focus on Traumatic Brain Injury, Pain, and Alcohol Withdrawal
ABSTRACT

Antiepileptic drugs (AEDs), have demonstrated efficacy treating a number of acute conditions, encompassing a broad range of symptoms and syndromes, in addition to being first-line treatment for epilepsy. Clinically, since their inception, AEDs have been used off-label for acute and chronic medical conditions, both as primary and as adjuvant therapies. In this review, we describe the observed clinical effectiveness of AEDs across a set of commonly encountered acute conditions in the general hospital: traumatic brain injury, pain, alcohol withdrawal. In describing the individual benefits and usages of specific agents, the applicability of these agents to other common neuropsychiatric conditions may be further explored.


Cite this paper
Nejad, S. , Chuang, K. , Hirschberg, R. , Aquino, P. and Fricchione, G. (2014) The Use of Antiepileptic Drugs in Acute Neuropsychiatric Conditions: Focus on Traumatic Brain Injury, Pain, and Alcohol Withdrawal. International Journal of Clinical Medicine, 5, 724-736. doi: 10.4236/ijcm.2014.512099.
References
[1]   Rho, J.M. and Sankar, R. (1999) The Pharmacologic Basis of Antiepileptic Drug Action. Epilepsia, 40, 1471-1483.
http://dx.doi.org/10.1111/j.1528-1157.1999.tb02029.x

[2]   Shorvon, S.D. (2009) Drug Treatment of Epilepsy in the Century of the ILAE: The First 50 Years, 1909-1958. Epilepsia, 50, 69-92.
http://dx.doi.org/10.1111/j.1528-1167.2009.02041.x

[3]   Armijo, J.A., Adin, J. and Sanchez, M.B. (2006) Mecanismo de acción de los antiepilépticos y nuevos antiepilépticos. Revue Neurologique, 43, S17-S41.

[4]   Chouinard, G. (2006) The Search for New Off-Label Indications for Antidepressant, Antianxiety, Antipsychotic and Anticonvulsant Drugs. Journal of Psychiatry and Neuroscience, 31, 168-176.

[5]   Langlois, J.A., Rutland-Brown, W. and Wald, M.M. (2006) The Epidemiology and Impact of Traumatic Brain Injury: A Brief Overview. The Journal of Head Trauma Rehabilitation, 21, 375-378.
http://dx.doi.org/10.1097/00001199-200609000-00001

[6]   Yasseen, B., Colantonio, A. and Ratcliff, G. (2008) Prescription Medication Use in Persons Many Years Following Traumatic Brain Injury. Brain Injury, 22, 752-757.
http://dx.doi.org/10.1080/02699050802320132

[7]   Chatham Showalter, P.E. and Kimmel, D.N. (2000) Agitated Symptom Response to Divalproex Following Acute Brain Injury. The Journal of Neuropsychiatry & Clinical Neurosciences, 12, 395-397.
http://dx.doi.org/10.1176/appi.neuropsych.12.3.395

[8]   Chatham-Showalter, P.E. (1996) Carbamazepine for Combativeness in Acute Traumatic Brain Injury. The Journal of Neuropsychiatry & Clinical Neurosciences, 8, 96-99.
http://dx.doi.org/10.1046/j.1528-1157.44.s10.4.x

[9]   Schierhout, G. and Roberts, I. (2012) Antiepileptic Drugs for Preventing Seizures Following Acute Traumatic Brain Injury. Cochrane Database of Systematic Reviews, 2012, Article ID: CD000173.

[10]   Frey, L.C. (2003) Epidemiology of Posttraumatic Epilepsy: A Critical Review. Epilepsia, 44, 11-17.

[11]   Lowenstein, D.H. (2009) Epilepsy after Head Injury: An Overview. Epilepsia, 50, 4-9.
http://dx.doi.org/10.1111/j.1528-1167.2008.02004.x

[12]   Fugate, L.P., Spacek, L.A., Kresty, L.A., Levy, C.E., Johnson, J.C. and Mysiw, W.J. (1997) Measurement and Treatment of Agitation Following Traumatic Brain Injury: II. A Survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation. Archives of Physical Medicine and Rehabilitation, 78, 924-928.
http://dx.doi.org/10.1016/S0003-9993(97)90051-4

[13]   Jones, K.E., Puccio, A.M., Harshman, K.J., Falcione, B., Benedict, N., Jankowitz, B.T., Stippler, M., Fischer, M., Sauber-Schatz, E.K., Fabio, A., Darby, J.M. and Okonkwo, D.O. (2008) Levetiracetam versus Phenytoin for Seizure Prophylaxis in Severe Traumatic Brain Injury. Neurosurgical Focus, 25, E3.
http://dx.doi.org/10.3171/FOC.2008.25.10.E3

[14]   Fugate, L.P., Spacek, L.A., Kresty, L.A., Levy, C.E., Johnson, J.C. and Mysiw, W.J. (1997) Definition of Agitation Following Traumatic Brain Injury: I. A Survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation. Archives of Physical Medicine and Rehabilitation, 78, 917-923.
http://dx.doi.org/10.1016/S0003-9993(97)90050-2

[15]   (1989) Oxford English Dictionary. 2nd Edition, Oxford University Press, Oxford.

[16]   Hagen, C., Malcmus, D. and Durham, P. (1979) Rehabilitation of the Head of Injured Adult: Comprehensive Physical Management. Professional Staff Association of Rancho Los Amigos Hospital, Downey, 87-89.

[17]   Lombard, L.A. and Zafonte, R.D. (2005) Agitation after Traumatic Brain Injury: Considerations and Treatment Options. American Journal of Physical Medicine & Rehabilitation, 84, 797-812.
http://dx.doi.org/10.1097/01.phm.0000179438.22235.08

[18]   Sandel, M.E. and Mysiw, W.J. (1996) The Agitated Brain Injured Patient. Part 1: Definitions, Differential Diagnosis, and Assessment. Archives of Physical Medicine and Rehabilitation, 77, 617-623.
http://dx.doi.org/10.1016/S0003-9993(96)90306-8

[19]   Wilson, M.S., Gibson, C.J. and Hamm, R.J. (2003) Haloperidol, but Not Olanzapine, Impairs Cognitive Performance after Traumatic Brain Injury in Rats. American Journal of Physical Medicine & Rehabilitation, 82, 871-879.
http://dx.doi.org/10.1097/01.PHM.0000091982.33232.CB

[20]   Rao, N., Jellinek, H.M. and Woolston, D.C. (1985) Agitation in Closed Head Injury: Haloperidol Effects on Rehabilitation Outcome. Archives of Physical Medicine and Rehabilitation, 66, 30-34.

[21]   Persinger, M.A. (2000) Subjective Improvement Following Treatment with Carbamazepine (Tegretol) for a Subpopulation of Patients with Traumatic Brain Injuries. Perceptual and Motor Skills, 90, 37-40.
http://dx.doi.org/10.2466/pms.2000.90.1.37

[22]   Stuppaeck, C.H., Pycha, R., Miller, C., Whitworth, A.B., Oberbauer, H. and Fleischhacker, W.W. (1992) Carbamazepine versus Oxazepam in the Treatment of Alcohol Withdrawal: A Double-Blind Study. Alcohol and Alcoholism, 27, 153-158.

[23]   Small, J.G., Klapper, M.H., Milstein, V., Kellams, J.J., Miller, M.J., Marhenke, J.D. and Small, I.F. (1991) Carbamazepine Compared with Lithium in the Treatment of Mania. JAMA Psychiatry, 48, 915-921.
http://dx.doi.org/10.1001/archpsyc.1991.01810340047006

[24]   Massagli, T.L. (1991) Neurobehavioral Effects of Phenytoin, Carbamazepine, and Valproic Acid: Implications for Use in Traumatic Brain Injury. Archives of Physical Medicine and Rehabilitation, 72, 219-226.

[25]   Dikmen, S.S., Machamer, J.E., Winn, H.R., Anderson, G.D. and Temkin, N.R. (2000) Neuropsychological Effects of Valproate in Traumatic Brain Injury: A Randomized Trial. Neurology, 54, 895-902.
http://dx.doi.org/10.1212/WNL.54.4.895

[26]   Smith Jr., K.R., Goulding, P.M., Wilderman, D., Goldfader, P.R., Holterman-Hommes, P. and Wei, F.F. (1994) Neurobehavioral Effects of Phenytoin and Carbamazepine in Patients Recovering from Brain Trauma: A Comparative Study. JAMA Neurology, 51, 653-660.
http://dx.doi.org/10.1001/archneur.1994.00540190029012

[27]   Azouvi, P., Jokic, C., Attal, N., Denys, P., Markabi, S. and Bussel, B. (1999) Carbamazepine in Agitation and Aggressive Behaviour Following Severe Closed-Head Injury: Results of an Open Trial. Brain Injury, 13, 797-804.
http://dx.doi.org/10.1080/026990599121188

[28]   Tang, V., Warden, J., Cullen, N. and Rutledge, E. (2007) To-piramate in Traumatic Brain Injury: Adverse Effects on Cognitive Function. Journal of Head Trauma Rehabilitation, 22, 409-410.
http://dx.doi.org/10.1097/01.HTR.0000300236.21114.bc

[29]   Lee, H.W., Jung, D.K., Suh, C.K., Kwon, S.H. and Park, S.P. (2006) Cognitive Effects of Low-Dose Topiramate Monotherapy in Epilepsy Patients: A 1-Year Follow-Up. Epilepsy & Behavior, 8, 736-741.
http://dx.doi.org/10.1016/j.yebeh.2006.03.006

[30]   Childers, M.K. and Holland, D. (1997) Psychomotor Agitation Following Gabapentin Use in Brain Injury. Brain Injury, 11, 537-540.
http://dx.doi.org/10.1080/713802187

[31]   Helmstaedter, C., Fritz, N.E., Kockelmann, E., Kosanetzky, N. and Elger, C.E. (2008) Positive and Negative Psychotropic Effects of Levetiracetam. Epilepsy & Behavior, 13, 535-541.
http://dx.doi.org/10.1016/j.yebeh.2008.05.012

[32]   Baguley, I.J., Heriseanu, R.E., Gurka, J.A., Nordenbo, A. and Cameron, I.D. (2007) Gabapentin in the Management of Dysautonomia Following Severe Traumatic Brain Injury: A Case Series. Journal of Neurology, Neurosurgery & Psychiatry, 78, 539-541.
http://dx.doi.org/10.1136/jnnp.2006.096388

[33]   Willmore, L.J. (2005) Antiepileptic Drugs and Neuroprotection: Current Status and Future Roles. Epilepsy & Behavior, 7, 25-28.
http://dx.doi.org/10.1016/j.yebeh.2005.08.006

[34]   Nejad, S. and Alpay, M. (2010) Pain Patients. In: Stern, T.A., Fricchione, G.L., Cassem, E.H., Jellinek, M. and Rosenbaum, J.F., Eds., MGH Handbook of General Hospital Psychiatry, Saunders, Washington D.C., 211-236.
http://dx.doi.org/10.1016/B978-1-4377-1927-7.00018-2

[35]   Blom, S. (1962) Trigeminal Neuralgia: Its Treatment with a New Anticonvulsant Drug (G-32883). Lancet, 279, 839-840.
http://dx.doi.org/10.1016/S0140-6736(62)91847-0

[36]   Rogawski, M.A. and Loscher, W. (2004) The Neurobi-ology of Antiepileptic Drugs for the Treatment of Nonepileptic Conditions. Nature Medicine, 10, 685-692.
http://dx.doi.org/10.1038/nm1074

[37]   Jensen, T.S. (2002) Anticonvulsants in Neuropathic Pain: Rationale and Clinical Evidence. European Journal of Pain, 6, 61-68.

[38]   Maciewicz, R., Bouckoms, A. and Martin, J.B. (1985) Drug Therapy of Neuropathic Pain. Clinical Journal of Pain, 1, 39-45.
http://dx.doi.org/10.1097/00002508-198501010-00006

[39]   Hering, R. and Kuritzky, A. (1989) Sodium Valproate in the Treatment of Cluster Headache: An Open Clinical Trial. Cephalalgia, 9, 195-198.
http://dx.doi.org/10.1046/j.1468-2982.1989.0903195.x

[40]   Freitag, F.G., Collins, S.D., Carlson, H.A., Goldstein, J., Saper, J., Silberstein, S., Mathew, N., Winner, P.K., Deaton, R. and Sommerville, K. (2002) A Randomized Trial of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis. Neurology, 58, 1652-1659.
http://dx.doi.org/10.1212/WNL.58.11.1652

[41]   Backonja, M., Beydoun, A., Edwards, K.R., Schwartz, S.L., Fonseca, V., Hes, M., LaMoreaux, L. and Garofalo, E. (1998) Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients with Diabetes Mellitus: A Randomized Controlled Trial. JAMA, 280, 1831-1836.
http://dx.doi.org/10.1001/jama.280.21.1831

[42]   Rowbotham, M., Harden, N., Stacey, B., Bernstein, P. and Magnus-Miller, L. (1998) Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial. JAMA, 280, 1837-1842.
http://dx.doi.org/10.1001/jama.280.21.1837

[43]   Hahn, K., Arendt, G., Braun, J.S., von Giesen, H.J., Husstedt, I.W., Maschke, M., Straube, M.E. and Schielke, E. (2004) A Placebo-Controlled Trial of Gabapentin for Painful HIV-Associated Sensory Neuropathies. Journal of Neurology, 251, 1260-1266.
http://dx.doi.org/10.1007/s00415-004-0529-6

[44]   Caraceni, A., Zecca, E., Bonezzi, C., Arcuri, E., Yaya Tur, R., Maltoni, M., Visentin, M., Gorni, G., Martini, C., Tirelli, W., Barbieri, M. and De Conno, F. (2004) Gabapentin for Neuropathic Cancer Pain: A Randomized Controlled Trial from the Gabapentin Cancer Pain Study Group. Journal of Clinical Oncology, 22, 2909-2917.
http://dx.doi.org/10.1200/JCO.2004.08.141

[45]   Lesser, H., Sharma, U., La-Moreaux, L. and Poole, R.M. (2004) Pregabalin Relieves Symptoms of Painful Diabetic Neuropathy: A Randomized Controlled Trial. Neurology, 63, 2104-2110.
http://dx.doi.org/10.1212/01.WNL.0000145767.36287.A1

[46]   Sabatowski, R., Galvez, R., Cherry, D.A., Jacquot, F., Vincent, E., Maisonobe, P. and Versavel, M. (2004) Pregabalin Reduces Pain and Improves Sleep and Mood Disturbances in Patients with Post-Herpetic Neuralgia: Results of a Randomised, Placebo-Controlled Clinical Trial. Pain, 109, 26-35.
http://dx.doi.org/10.1016/j.pain.2004.01.001

[47]   Vinik, A.I., Tuchman, M., Safirstein, B., Corder, C., Kirby, L., Wilks, K., Quessy, S., Blum, D., Grainger, J., White, J. and Silver, M. (2007) Lamotrigine for Treatment of Pain Associated with Diabetic Neuropathy: Results of Two Randomized, Double-Blind, Placebo-Controlled Studies. Pain, 128, 169-179.
http://dx.doi.org/10.1016/j.pain.2006.09.040

[48]   Jose, V.M., Bhansali, A., Hota, D. and Pandhi, P. (2007) Randomized Double-Blind Study Comparing the Efficacy and Safety of Lamotrigine and Amitriptyline in Painful Diabetic Neuropathy. Diabetic Medicine, 24, 377-383.
http://dx.doi.org/10.1111/j.1464-5491.2007.02093.x

[49]   Silver, M., Blum, D., Grainger, J., Hammer, A.E. and Quessy, S. (2007) Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain. Journal of Pain and Symptom Management, 34, 446-454.
http://dx.doi.org/10.1016/j.jpainsymman.2006.12.015

[50]   Rao, R.D., Flynn, P.J., Sloan, J.A., Wong, G.Y., Novotny, P., Johnson, D.B., Gross, H.M., Renno, S.I., Nashawaty, M. and Loprinzi, C.L. (2008) Efficacy of Lamotrigine in the Management of Chemotherapy-Induced Peripheral Neuropathy. Cancer, 112, 2802-2808.
http://dx.doi.org/10.1002/cncr.23482

[51]   Wiffen, P.J. and Rees, J. (2007) Lamotrigine for Acute and Chronic Pain. Cochrane Database of Systematic Reviews, Article ID: CD006044.

[52]   Addolorato, G., Leggio, L., Abenavoli, L. and Gasbarrini, G. (2005) Neurobiochemical and Clinical Aspects of Craving in Alcohol Addiction: A Review. Addictive Behaviors, 30, 1209-1224.
http://dx.doi.org/10.1016/j.addbeh.2004.12.011

[53]   Chastain, G. (2006) Alcohol, Neurotransmitter Systems, and Behavior. Journal of General Psychology, 133, 329-335.
http://dx.doi.org/10.3200/GENP.133.4.329-335

[54]   Carta, M., Olivera, D.S., Dettmer, T.S. and Valenzuela, C.F. (2002) Ethanol Withdrawal Upregulates Kainate Receptors in Cultured Rat Hippocampal Neurons. Neuroscience Letters, 327, 128-132.
http://dx.doi.org/10.1016/S0304-3940(02)00399-3

[55]   Haugbol, S.R., Ebert, B. and Ulrichsen, J. (2005) Upregulation of Glutamate Receptor Subtypes during Alcohol Withdrawal in Rats. Alcohol and Alcoholism, 40, 89-95.
http://dx.doi.org/10.1093/alcalc/agh117

[56]   Littleton, J. (1998) Neurochemical Mechanisms Underlying Alcohol Withdrawal. Alcohol Health and Research World, 22, 13-24.

[57]   Ballenger, J.C. and Post, R.M. (1978) Kindling as a Model for Alcohol Withdrawal Syndromes. British Journal of Psychiatry, 133, 1-14.
http://dx.doi.org/10.1192/bjp.133.1.1

[58]   Malcolm, R.J. (2003) GABA Systems, Benzodiazepines, and Substance Dependence. Journal of Clinical Psychiatry, 64, 36-40.

[59]   Bayard, M., McIntyre, J., Hill, K.R. and Woodside Jr., J. (2004) Alcohol Withdrawal Syndrome. American Family Physician, 69, 1443-1450.

[60]   Becker, H.C. and Littleton, J.M. (1996) The Alcohol Withdrawal “Kindling” Phenomenon: Clinical and Experimental Findings. Alcoholism: Clinical and Experimental Research, 20, 121a-124a.
http://dx.doi.org/10.1111/j.1530-0277.1996.tb01760.x

[61]   Saitz, R., Mayo-Smith, M.F., Roberts, M.S., Redmond, H.A., Bernard, D.R. and Calkins, D.R. (1994) Individualized Treatment for Alcohol Withdrawal: A Randomized Double-blind Controlled Trial. JAMA, 272, 519-523.
http://dx.doi.org/10.1001/jama.1994.03520070039035

[62]   Mayo-Smith, M.F. (1997) Pharmacological Man-agement of Alcohol Withdrawal: A Meta-Analysis and Evidence-Based Practice Guideline. JAMA, 278, 144-151.
http://dx.doi.org/10.1001/jama.1997.03550020076042

[63]   Saitz, R., Horton, N.J., Larson, M.J., Winter, M. and Samet, J.H. (2005) Primary Medical Care and Reductions in Addiction Severity: A Prospective Cohort Study. Addiction, 100, 70-78.
http://dx.doi.org/10.1111/j.1360-0443.2005.00916.x

[64]   Rogawski, M.A. (2005) Update on the Neurobiology of Alcohol Withdrawal Seizures. Epilepsy Currents, 5, 225-230. http://dx.doi.org/10.1111/j.1535-7511.2005.00071.x

[65]   Leggio, L., Kenna, G.A. and Swift, R.M. (2008) New Developments for the Pharmacological Treatment of Alcohol Withdrawal Syndrome. A Focus on Non-Benzodiazepine GABAergic Medications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 1106-1117.
http://dx.doi.org/10.1016/j.pnpbp.2007.09.021

[66]   Armijo, J.A., Shushtarian, M., Valdizan, E.M., Cuadrado, A., de las Cuevas, I. and Adin, J. (2005) Ion Channels and Epilepsy. Current Pharmaceutical Design, 11, 1975-2003.
http://dx.doi.org/10.2174/1381612054021006

[67]   Malcolm, R., Myrick, H., Brady, K.T. and Ballenger, J.C. (2001) Update on Anticonvulsants for the Treatment of Alcohol Withdrawal. American Journal on Addictions, 10, s16-s23.
http://dx.doi.org/10.1080/10550490150504100

[68]   Ait-Daoud, N., Malcolm Jr., R.J. and Johnson, B.A. (2006) An Overview of Medications for the Treatment of Alcohol Withdrawal and Alcohol Dependence with an Emphasis on the Use of Older and Newer Anticonvulsants. Addictive Behaviors, 31, 1628-1649.
http://dx.doi.org/10.1016/j.addbeh.2005.12.029

[69]   Chu, N.S. (1979) Carbamazepine: Prevention of Alcohol Withdrawal Seizures. Neurology, 29, 1397-1401.
http://dx.doi.org/10.1212/WNL.29.10.1397

[70]   Strzelec, J.S. and Czarnecka, E. (2001) Influence of Clonazepam and Carbamazepine on Alcohol Withdrawal Syndrome, Preference and Development of Tolerance to Ethanol in Rats. Polish Journal of Pharmacology, 53, 117-124.

[71]   Malcolm, R., Myrick, H., Roberts, J., Wang, W., Anton, R.F. and Ballenger, J.C. (2002) The Effects of Carbamazepine and Lorazepam on Single versus Multiple Previous Alcohol Withdrawals in an Outpatient Randomized Trial. Journal of General Internal Medicine, 17, 349-355.
http://dx.doi.org/10.1007/s11606-002-0038-1

[72]   Sullivan, J.T., Sykora, K., Schneiderman, J., Naranjo, C.A. and Sellers, E.M. (1989) Assessment of Alcohol Withdrawal: The Revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). British Journal of Addiction, 84, 1353-1357.
http://dx.doi.org/10.1111/j.1360-0443.1989.tb00737.x

[73]   Keck Jr., P.E., McElroy, S.L. and Friedman, L.M. (1992) Valproate and Carbamazepine in the Treatment of Panic and Posttraumatic Stress Disorders, Withdrawal States, and Behavioral Dyscontrol Syndromes. Journal of Clinical Psychopharmacology, 12, 36S-41S.
http://dx.doi.org/10.1097/00004714-199202001-00006

[74]   Loscher, W. (2002) Basic Pharmacology of Valproate. CNS Drugs, 16, 669-694.
http://dx.doi.org/10.2165/00023210-200216100-00003

[75]   Reoux, J.P., Saxon, A.J., Malte, C.A., Baer, J.S. and Sloan, K.L. (2001) Divalproex Sodium in Alcohol Withdrawal: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Alcoholism: Clinical and Experimental Research, 25, 1324-1329.
http://dx.doi.org/10.1111/j.1530-0277.2001.tb02354.x

[76]   Hillbom, M., Tokola, R., Kuusela, V., Karkkainen, P., Kalli-Lemma, L., Pilke, A. and Kaste, M. (1989) Prevention of Alcohol Withdrawal Seizures with Carbamazepine and Valproic Acid. Alcohol, 6, 223-226.
http://dx.doi.org/10.1016/0741-8329(89)90022-0

[77]   Teichberg, V.I., Tal, N., Goldberg, O. and Luini, A. (1984) Barbiturates, Alcohols and the CNS Excitatory Neurotransmission: Specific Effects on the Kainate and Quisqualate Receptors. Brain Research, 291, 285-292.
http://dx.doi.org/10.1016/0006-8993(84)91260-5

[78]   Ives, T.J., Mooney, A.J. and Gwyther, R.E. (1991) Phar-macokinetic Dosing of Phenobarbital in the Treatment of Alcohol Withdrawal Syndrome. Southern Medical Journal, 84, 18-21.
http://dx.doi.org/10.1097/00007611-199101000-00006

[79]   Rosenson, J., Clements, C., Simon, B., Vieaux, J., Graffman, S., Vahidnia, F., Cisse, B., Lam, J. and Alter, H. (2013) Phenobarbital for Acute Alcohol Withdrawal: A Prospective Randomized Double-Blind Placebo-Controlled Study. The Journal of Emergency Medicine, 44, 592.e2-598.e2.

[80]   Chatterjee, C.R. and Ringold, A.L. (1999) A Case Report of Reduction in Alcohol Craving and Protection against Alcohol Withdrawal by Gabapentin. Journal of Clinical Psychiatry, 60, 617.
http://dx.doi.org/10.4088/JCP.v60n0911

[81]   Bonnet, U., Banger, M., Leweke, F.M., Maschke, M., Kowalski, T. and Gastpar, M. (1999) Treatment of Alcohol Withdrawal Syndrome with Gabapentin. Pharmacopsychiatry, 32, 107-109.
http://dx.doi.org/10.1055/s-2007-979203

[82]   Bozikas, V., Petrikis, P., Gamvrula, K., Savvidou, I. and Karavatos, A. (2002) Treatment of Alcohol Withdrawal with Gabapentin. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 197-199.
http://dx.doi.org/10.1016/S0278-5846(01)00234-2

[83]   Karam-Hage, M. and Brower, K.J. (2000) Gabapentin Treatment for Insomnia Associated with Alcohol Dependence. American Journal of Psychiatry, 157, 151.

[84]   Myrick, H., Malcolm, R. and Brady, K.T. (1998) Gabapentin Treatment of Alcohol Withdrawal (Letter). American Journal of Psychiatry, 155, 1632.

[85]   Voris, J., Smith, N.L., Rao, S.M., Thorne, D.L. and Flowers, Q.J. (2003) Gabapentin for the Treatment of Ethanol Withdrawal. Substance Abuse, 24, 129-132.

[86]   Rustembegovic, A., Sofic, E., Tahirovic, I. and Kundurovic, Z. (2004) A Study of Gabapentin in the Treatment of Tonic-Clonic Seizures of Alcohol Withdrawal Syndrome. Medicinski Arhiv, 58, 5-6.

[87]   Myrick, H., Malcolm, R., Randall, P.K., Boyle, E., Anton, R.F., Becker, H.C. and Randall, C.L. (2009) A Double-Blind Trial of Gabapentin Versus Lorazepam in the Treatment of Alcohol Withdrawal. Alcoholism: Clinical and Experimental Research, 33, 1582-1588.
http://dx.doi.org/10.1111/j.1530-0277.2009.00986.x

[88]   Bonnet, U., Specka, M., Hamzavi Abedi, R., Wiltfang, J. and Scherbaum, N. (2009) Severe Protracted Alcohol Withdrawal Syndrome: Prevalence and Pharmacological Treatment at an Inpatient Detoxification Unit—A Naturalistic Study. Pharmacopsychiatry, 42, 76-78.
http://dx.doi.org/10.1055/s-0028-1103292

 
 
Top